Neural Crest‐Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion
dc.contributor.author | Fang, Fang | en_US |
dc.contributor.author | Sun, Shaogang | en_US |
dc.contributor.author | Wang, Li | en_US |
dc.contributor.author | Guan, Jun‐lin | en_US |
dc.contributor.author | Giovannini, Marco | en_US |
dc.contributor.author | Zhu, Yuan | en_US |
dc.contributor.author | Liu, Fei | en_US |
dc.date.accessioned | 2015-07-01T20:55:43Z | |
dc.date.available | 2016-08-08T16:18:39Z | en |
dc.date.issued | 2015-07 | en_US |
dc.identifier.citation | Fang, Fang; Sun, Shaogang; Wang, Li; Guan, Jun‐lin ; Giovannini, Marco; Zhu, Yuan; Liu, Fei (2015). "Neural Crestâ Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion." Journal of Bone and Mineral Research 30(7): 1195-1205. | en_US |
dc.identifier.issn | 0884-0431 | en_US |
dc.identifier.issn | 1523-4681 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/111902 | |
dc.description.abstract | Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either TSC1 or TSC2. TSC has high frequency of osseous manifestations such as sclerotic lesions in the craniofacial region. However, an animal model that replicates TSC craniofacial bone lesions has not yet been described. The roles of Tsc1 and the sequelae of Tsc1 dysfunction in bone are unknown. In this study, we generated a mouse model of TSC with a deletion of Tsc1 in neural crest‐derived (NCD) cells that recapitulated the sclerotic craniofacial bone lesions in TSC. Analysis of this mouse model demonstrated that TSC1 deletion led to enhanced mTORC1 signaling in NCD bones and the increase in bone formation is responsible for the aberrantly increased bone mass. Lineage mapping revealed that TSC1 deficient NCD cells overpopulated the NCD bones. Mechanistically, hyperproliferation of osteoprogenitors at an early postnatal stage accounts for the increased osteoblast pool. Intriguingly, early postnatal treatment with rapamycin, an mTORC1 inhibitor, can completely rescue the aberrant bone mass, but late treatment cannot. Our data suggest that enhanced mTOR signaling in NCD cells can increase bone mass through enlargement of the osteoprogenitor pool, which likely explains the sclerotic bone lesion observed in TSC patients. © 2015 American Society for Bone and Mineral Research. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | SCLEROTIC | en_US |
dc.subject.other | OSTEOPROGENITOR | en_US |
dc.subject.other | TUBEROUS SCLEROSIS | en_US |
dc.subject.other | mTORC1 | en_US |
dc.subject.other | NEURAL CREST | en_US |
dc.subject.other | CRANIOFACIAL | en_US |
dc.subject.other | RAPAMYCIN | en_US |
dc.subject.other | OSTEOBLASTS | en_US |
dc.title | Neural Crest‐Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialities | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/111902/1/jbmr2447.pdf | |
dc.identifier.doi | 10.1002/jbmr.2447 | en_US |
dc.identifier.source | Journal of Bone and Mineral Research | en_US |
dc.identifier.citedreference | Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschlager M. Role of the tuberous sclerosis gene‐2 product in cell cycle control. Loss of the tuberous sclerosis gene‐2 induces quiescent cells to enter S phase. J Biol Chem 1997; 272: 29301 – 29308. | en_US |
dc.identifier.citedreference | Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999; 21: 70 – 71. | en_US |
dc.identifier.citedreference | Liu F, Fang F, Yuan H, et al. Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J Bone Miner Res 2013; 28: 2414 – 2430. | en_US |
dc.identifier.citedreference | Wang J, Xi L, Hunt JL, et al. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004; 64: 1861 – 1866. | en_US |
dc.identifier.citedreference | Feldkamp LA, Goldstein SA, Parfitt AM, Jesion G, Kleerekoper M. The direct examination of three‐dimensional bone architecture in vitro by computed tomography. J Bone Miner Res 1989; 4: 3 – 11. | en_US |
dc.identifier.citedreference | McCreadie BR, Goulet RW, Feldkamp LA, Goldstein SA. Hierarchical structure of bone and micro‐computed tomography. Adv Exp Med Biol 2001; 496: 67 – 83. | en_US |
dc.identifier.citedreference | Kuhn JL, Goldstein SA, Feldkamp LA, Goulet RW, Jesion G. Evaluation of a microcomputed tomography system to study trabecular bone structure. J Orthop Res 1990; 8: 833 – 842. | en_US |
dc.identifier.citedreference | Liu F, Lee SK, Adams DJ, Gronowicz GA, Kream BE. CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment. Bone 2007; 40: 1135 – 1143. | en_US |
dc.identifier.citedreference | Chandhoke TK, Huang YF, Liu F, et al. Osteopenia in transgenic mice with osteoblast‐targeted expression of the inducible cAMP early repressor. Bone 2008; 43: 101 – 109. | en_US |
dc.identifier.citedreference | Liu F, Fang F, Yuan H, et al. Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J Bone Miner Res 2013. | en_US |
dc.identifier.citedreference | Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013; 28: 2 – 17. | en_US |
dc.identifier.citedreference | Zheng H, Chang L, Patel N, et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell 2008; 13: 117 – 128. | en_US |
dc.identifier.citedreference | Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin‐deficient mice. Nature 1996; 382: 448 – 452. | en_US |
dc.identifier.citedreference | Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla‐containing proteins. J Cell Biol 2004; 165: 625 – 630. | en_US |
dc.identifier.citedreference | Umeoka S, Koyama T, Miki Y, Akai M, Tsutsui K, Togashi K. Pictorial review of tuberous sclerosis in various organs. Radiographics 2008; 28: e32. | en_US |
dc.identifier.citedreference | Wang Y, Kim E, Wang X, et al. ERK inhibition rescues defects in fate specification of Nf1‐deficient neural progenitors and brain abnormalities. Cell 2012; 150: 816 – 830. | en_US |
dc.identifier.citedreference | Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. MTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E‐BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24: 200 – 216. | en_US |
dc.identifier.citedreference | Rachdi L, Balcazar N, Osorio‐Duque F, et al. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1‐dependent manner. Proc Natl Acad Sci U S A 2008; 105: 9250 – 9255. | en_US |
dc.identifier.citedreference | Miloloza A, Rosner M, Nellist M, Halley D, Bernaschek G, Hengstschlager M. The TSC1 gene product, hamartin, negatively regulates cell proliferation. Hum Mol Genet 2000; 9: 1721 – 1727. | en_US |
dc.identifier.citedreference | Jin F, Wienecke R, Xiao GH, Maize JC, Jr., DeClue JE, Yeung RS. Suppression of tumorigenicity by the wild‐type tuberous sclerosis 2 (Tsc2) gene and its C‐terminal region. Proc Natl Acad Sci U S A 1996; 93: 9154 – 9159. | en_US |
dc.identifier.citedreference | Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS. The tuberin‐hamartin complex negatively regulates beta‐catenin signaling activity. J Biol Chem 2003; 278: 5947 – 5951. | en_US |
dc.identifier.citedreference | Lee KW, Yook JY, Son MY, et al. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev 2010; 19: 557 – 568. | en_US |
dc.identifier.citedreference | Singha UK, Jiang Y, Yu S, et al. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3‐E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 2008; 103: 434 – 446. | en_US |
dc.identifier.citedreference | Ogawa T, Tokuda M, Tomizawa K, et al. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast‐like osteosarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun 1998; 249: 226 – 230. | en_US |
dc.identifier.citedreference | Isomoto S, Hattori K, Ohgushi H, Nakajima H, Tanaka Y, Takakura Y. Rapamycin as an inhibitor of osteogenic differentiation in bone marrow‐derived mesenchymal stem cells. J Orthop Sci 2007; 12: 83 – 88. | en_US |
dc.identifier.citedreference | Shoba LN, Lee JC. Inhibition of phosphatidylinositol 3‐kinase and p70S6 kinase blocks osteogenic protein‐1 induction of alkaline phosphatase activity in fetal rat calvaria cells. J Cell Biochem 2003; 88: 1247 – 1255. | en_US |
dc.identifier.citedreference | Faghihi F, Baghaban Eslaminejad M, Nekookar A, Najar M, Salekdeh GH. The effect of purmorphamine and sirolimus on osteogenic differentiation of human bone marrow‐derived mesenchymal stem cells. Biomed Pharmacother 2013; 67: 31 – 38. | en_US |
dc.identifier.citedreference | Martin SK, Fitter S, Bong LF, et al. NVP‐BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res 2010; 25: 2126 – 2137. | en_US |
dc.identifier.citedreference | Xian L, Wu X, Pang L, et al. Matrix IGF‐1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 2012; 18: 1095 – 1101. | en_US |
dc.identifier.citedreference | Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14 Spec No. 2005; 2: R251 – R258. | en_US |
dc.identifier.citedreference | Laplante M, Sabatini DM. MTOR signaling in growth control and disease. Cell 2012; 149: 274 – 293. | en_US |
dc.identifier.citedreference | Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase‐activating protein complex toward Rheb. Curr Biol 2003; 13: 1259 – 1268. | en_US |
dc.identifier.citedreference | Holt JF, Dickerson WW. The osseous lesions of tuberous sclerosis. Radiology 1952; 58: 1 – 8. | en_US |
dc.identifier.citedreference | Morris BS, Garg A, Jadhav PJ. Tuberous sclerosis: a presentation of less‐commonly encountered stigmata. Australas Radiol 2002; 46: 426 – 430. | en_US |
dc.identifier.citedreference | Kobayashi T, Minowa O, Sugitani Y, et al. A germ‐line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A 2001; 98: 8762 – 8767. | en_US |
dc.identifier.citedreference | Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ‐line Tsc2 mutation in mice. Cancer Res 1999; 59: 1206 – 1211. | en_US |
dc.identifier.citedreference | Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex‐dependent lethality from liver hemangiomas, and up‐regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002; 11: 525 – 534. | en_US |
dc.identifier.citedreference | Riddle RC, Frey JL, Tomlinson RE, et al. Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis. Mol Cell Biol 2014. | en_US |
dc.identifier.citedreference | Jiang X, Iseki S, Maxson RE, Sucov HM, Morriss‐Kay GM. Tissue origins and interactions in the mammalian skull vault. Dev Biol 2002; 241: 106 – 116. | en_US |
dc.identifier.citedreference | Giovannini M, Robanus‐Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000; 14: 1617 – 1630. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.